Sharp Therapeutics Corp.
SHRXF
$1.76
-$1.24-41.41%
OTC PK
| 09/30/2025 | 06/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -22.74% | 5.77% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -27.70% | 8.45% | |||
| Operating Income | 27.70% | -8.45% | |||
| Income Before Tax | -294.15% | 117.18% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -294.15% | 117.18% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -294.15% | 117.18% | |||
| EBIT | 27.70% | -8.45% | |||
| EBITDA | 27.90% | -8.79% | |||
| EPS Basic | -292.55% | 116.31% | |||
| Normalized Basic EPS | -291.53% | 116.37% | |||
| EPS Diluted | -292.55% | 116.31% | |||
| Normalized Diluted EPS | -291.53% | 116.37% | |||
| Average Basic Shares Outstanding | 1.05% | 5.12% | |||
| Average Diluted Shares Outstanding | 1.05% | 5.12% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||